Venetoclax plus rituximab versus standard Waldenstrom treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Waldenstrom’s macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).
- Your WM must have measurable activity, usually a high IgM protein level, checked within 28 days before enrolling.
- You must need treatment now (for example anemia, low platelets, nerve symptoms, very thick blood symptoms, kidney problems from WM, bulky disease, or certain ongoing symptoms).
- You must not have had chemotherapy-type treatment before; rituximab is allowed if your last dose was at least 6 months ago.
- Your body must be able to tolerate study medicine: kidney tests, liver tests, and blood counts must meet minimum levels, and you should be well enough to do daily activities (Zubrod 0–2).
- You must be able to take pills by mouth, have no major uncontrolled infections, and avoid certain drug interactions (including no grapefruit/Seville oranges/starfruit near the start).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
Hear when a new Lymphoplasmacytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.